Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients

This study is a laboratory study focused on understanding ovarian cancer. Researchers will collect ascites fluid (fluid that can build up in the abdomen) from women with ovarian cancer during their surgery or a procedure called paracentesis (a way to remove fluid from the abdomen). This fluid contains cancer cells and immune cells, which will be used to test new immunotherapies (treatments that use your body's immune system to fight cancer) and create models to better study the disease. The goal is to find better ways to treat ovarian cancer. You may be able to join if you are a woman, 18 years or older, and are having surgery for suspected or confirmed ovarian cancer. This study is currently observational, meaning researchers are collecting samples and not testing a specific drug on participants.

Study design: This is an observational study planning to enroll 100 participants. It is not testing a specific drug directly on patients.
What's involved: You would provide ascites fluid during your cytoreductive surgery or paracentesis. No other procedures or visits are specified for participants.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint of collecting ascites fluid is measured at 5 years, but it's unclear if this refers to participant follow-up.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

Recruiting

Not specifiedAges 18+Observational

New Mexico Cancer Research Alliance

~100 participants

Updated 2025-05-22 on ClinicalTrials.gov

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis

Measured over 5 years

Conditions

Ovarian Cancer

Where it's being run

1 sites across 1 states

New Mexico1

Study leadership

Sarah Adams, MD · PRINCIPAL_INVESTIGATOR · UNM Comprehensive Cancer Center

Who to contact

Sarah Adams, MD

[email protected]

(505) 925-0461

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study

All participants will be eighteen years old or older

Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.

Ability to understand and the willingness to sign a written informed consent document.

Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell)

Women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry.

A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

Has not undergone a hysterectomy or bilateral oophorectomy; or

Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion

We do not intend to include participants if they are unable to provide informed consent for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners.

Minors under age eighteen.

Pregnant women.

Final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer

What this trial measures

Collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis5 years
To elucidate the conditions of the tumor environment that contribute to cancer dissemination in the peritoneal cavity through ex vivo evaluation of malignant ascites collected from women with ovarian, tubal, or primary peritoneal cancer.

Trialytics